Quiz|Articles|March 6, 2026

OncLive Weekly News Quiz (3/6/2026): Brush Up on Regulatory Splashes in Myeloma, RCC, and PV

Author(s)OncLive Staff
Fact checked by: Chris Ryan

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA recently approved teclistamab-cqyv (Tecvayli) in combination with daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of patients with relapsed/refractory multiple myeloma after at least 1 prior line of therapy, after the regulatory agency reviewed the application under the FDA Commissioner’s National Priority Review Voucher pilot program. The decision followed which February oncology approval that was also reviewed under the same program?



Latest CME